Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsRobert Berger, MD
Clinical InstructorAbout
Research
Publications
2024
Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids
Bar-Hai N, Ben-Yishay R, Arbili-Yarhi S, Herman N, Avidan-Noy V, Menes T, Mansour A, Awwad F, Balint-Lahat N, Goldinger G, Hout-Siloni G, Adileh M, Berger R, Ishay-Ronen D. Modeling epithelial-mesenchymal transition in patient-derived breast cancer organoids. Frontiers In Oncology 2024, 14: 1470379. PMID: 39469640, PMCID: PMC11513879, DOI: 10.3389/fonc.2024.1470379.Peer-Reviewed Original ResearchEpithelial-mesenchymal transitionPatient-derived breast cancer modelsCancer patientsCell plasticityTGF-bBreast cancer organoidsCancer cell plasticityBreast cancer modelBreast cancer patientsEMT-like featuresE-cadherin downregulationEMT-like processCancer modelsOrganoid linesCancer organoidsEpithelial plasticityInvasive phenotypeCellular plasticityE-cadherinOrganoidsPatientsCancerDedifferentiation processMorphological changesCytoskeletal reorganizationClass Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation
Ben-Yishay R, Globus O, Balint-Lahat N, Arbili-Yarhi S, Bar-Hai N, Bar V, Aharon S, Kosenko A, Zundelevich A, Berger R, Ishay-Ronen D. Class Effect Unveiled: PPARγ Agonists and MEK Inhibitors in Cancer Cell Differentiation. Cells 2024, 13: 1506. PMID: 39273076, PMCID: PMC11394433, DOI: 10.3390/cells13171506.Peer-Reviewed Original ResearchConceptsMEK inhibitorsBreast cancer cellsEpithelial-to-mesenchymal transitionCancer cellsPPARg agonistsDrug resistanceTherapeutic approachesTriple-negative breast cancerMurine breast cancer cellsAggressive breast cancer subtypeDevelopment of drug resistanceCancer cell plasticityBreast cancer subtypesCombination of pioglitazoneOvercome drug resistanceDedifferentiated cancer cellsBreast cancer progressionCancer cell differentiationCytoskeleton rearrangementLipid droplet accumulationCell trans-differentiationBreast cancerCancer subtypesCell plasticityTherapeutic strategiesA Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression
Majumder P, Grisanzio C, O'Connell F, Barry M, Brito J, Xu Q, Guney I, Berger R, Herman P, Bikoff R, Fedele G, Baek W, Wang S, Ellwood-Yen K, Wu H, Sawyers C, Signoretti S, Hahn W, Loda M, Sellers W. A Prostatic Intraepithelial Neoplasia-Dependent p27Kip1 Checkpoint Induces Senescence and Inhibits Cell Proliferation and Cancer Progression. Cancer Cell 2024, 42: 1126. PMID: 38866454, DOI: 10.1016/j.ccell.2024.05.008.Commentaries, Editorials and Letters
2019
Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study.
Antonarakis E, Piulats J, Gross-Goupil M, Goh J, Ojamaa K, Hoimes C, Vaishampayan U, Berger R, Sezer A, Alanko T, de Wit R, Li C, Omlin A, Procopio G, Fukasawa S, Tabata K, Park S, Feyerabend S, Drake C, Wu H, Qiu P, Kim J, Poehlein C, de Bono J. Pembrolizumab for Treatment-Refractory Metastatic Castration-Resistant Prostate Cancer: Multicohort, Open-Label Phase II KEYNOTE-199 Study. Journal Of Clinical Oncology 2019, 38: 395-405. PMID: 31774688, PMCID: PMC7186583, DOI: 10.1200/jco.19.01638.Peer-Reviewed Original ResearchConceptsMetastatic castration-resistant prostate cancerCastration-resistant prostate cancerDisease control rateDuration of responseCohort 1Cohort 3Cohort 2Endocrine therapyOverall survivalMedian durationProstate cancerAntitumor activityControl rateMetastatic castration-resistant prostate cancer treated with docetaxelBone-predominant metastatic castration-resistant prostate cancerMCRPC populationMedian duration of responsePD-L1-negative diseaseTreatment-related adverse eventsResponse rateBone-predominant diseaseObjective response rateSafety of pembrolizumabTargeted endocrine therapyPD-L1 expression
2017
The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017)
Golan T, Milella M, Ackerstein A, Berger R. The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017). Journal Of Experimental & Clinical Cancer Research 2017, 36: 192. PMID: 29282151, PMCID: PMC5745625, DOI: 10.1186/s13046-017-0668-0.Peer-Reviewed Original ResearchConceptsClinical trialsImmuno-oncologyImmune-checkpoint blockadeImmuno-oncology eraEra of personalized medicineEffective immunotherapy approachesPersonalized medicineOncology disease areasDrug development pathClinical trial designImmunotherapy approachesHematologic malignanciesOncology clinical trialsTranslational cancer researchTherapeutic optionsTreatment algorithmHemato-oncologyCancer patientsOncology communityCancer biologyCancerOncologyTrial designTrialsPatients